#130 Life Science Industry

Buildings of Tomorrow ·

Show notes

This week, Buildings of Tomorrow takes you into another field and makes you discover what the life science industry is. Chad House, head of Life Science for Americas at Siemens Smart Infrastructure, will tell you all about the characteristics but also the challenges and opportunities that emerge and that the industry takes advantage of.

Transcript

Hello and welcome to Buildings of Tomorrow. My name is John Lester, and in today's episode we are talking about the life science industry. What is it and some of the really key challenges and, and opportunities that the life science industry have to handle and really have the chance to take advantage of. I'm joined today by Chad House. He is the head of Life Science for Americas at Siemens Smart-Infrastructure. Chad, thank you so much for joining us today. Thank you for having me, John. It's an absolute pleasure. So today we're talking about life sciences. What do we mean when we talk about life science or the life science industry? Yeah, yeah. That's a good question, John, because, you know, there's a lot of different, uh, you know, definitions of life science. You know, our definition of life science is Although, you know, Siemens classifies us as a vertical market, you know, really if you look at the life science market, we're really a horizontal market, and what I mean by that is that we really cross over into multiple vertical markets such as the higher education market. You know, they do a lot of life science labs, R&D, you know, on campuses. government type of facilities, you know, that's the National Institutes of Health, you know, the CDC of the world there as well. So, you know, those type of lab environments as well is very critical for our success along with, you know, local municipalities with, you know, pharmacy or forensics labs. So those are often, you know, kind of overlooked, you know, for labs and critical environments there. And then, you know, the the big pharma, you know, the pharmaceutical market is a big market for us as well, you know, that's the, you know, the Johnson and Johnson's, the AstraZeneca, the Pfizers of the world, Merck, you know, just to name a few of our key customers out there in the pharma world. Um, and then, you know, if you really look at the healthcare market, I mean healthcare is a, you know, has a lot of lab life science pressurized spaces that, you know, we really get involved with in that market as well. So that's why we consider, you know, life science a horizontal market, you know, within, you know, the vertical market for life sciences. I understand and you just mentioned a whole lot of different applications and while the While the space itself or the function of some of the technology might be the same, the applications are really, really broad and, and probably come with their own challenges above and beyond, you know, the, the technical challenges that you have to undertake. Yes, absolutely. You know, today we'll probably look a little bit, we'll focus a little bit in some of the segments of this market. And so give us a bit of an idea when we're talking about, you know, the The government agencies, you know, your CDCs, your, your WHOs, these kinds of organizations, your large pharma manufacturers, Pfizer, etc. What, what are they, what are they really up against? What are some of the key challenges that they find in this industry that keep them up at night? Yeah, yeah, that's, that's, uh, you know, there's a lot of challenges that a lot of our customers are facing, you know, these days as well. But if you look at the life science market, The the the customers that, you know, are into the life science market, if you look at, they really enjoy, you know, their, their, their spaces, their facilities, you know, they really take a lot of pride into their, their research spaces, but if you look at the market, you know, there's a lot of aging infrastructure out there that really needs to be, you know, taken advantage of, you know, upgrades and, you know, bringing them up to modern technology, you know, for today. Um, you know, go to market faster is another key challenge for a lot of these customers, and what I mean by that is, you know, just like any, any other market out there, you know, they have to really be on the forefront and be quick to, you know, get out of the gate and get to market. Of course, competition is becoming greater between, you know, pharmaceutical customers and, you know, life science customers as well. And then, you know, the big one too is actually retracting and attracting and retaining actually the top researchers, you know, that really goes for, you know, the higher education or government type of facilities where they're trying to, you know, They're trying to attract, you know, the top researchers to come to their facilities and do the research so they can actually get, you know, the top research grants and the and the monies that are available there. So how do they do that? You know, they really have to be on their game and they have to, you know, have their facilities be, you know, top notch, state of the art technology, you know, if these top researchers have, you know, the choice to go from one site to another site. You know, of course they're going to pick probably the best looking building out there that has the best technology out there as opposed to, you know, one that's maybe has antiquated technology, hasn't been upgraded over the years. So that's, you know, a big challenge out there, Mark, is the big aging infrastructure and then, you know, not to mention, you know, it's just the competition out there that's out there. Yeah, and that aging infrastructure is a difficult one because when when we're talking about, you know, these, these research grants, you know, these, these really detailed, focused, and in many cases long-term processes where they're doing research and development, you know, you can't compromise on the environmental space or the integrity of the space or the integrity of, of the process itself. Is that That challenge must is quite a conflicting one against you when you're talking about aging infrastructure, when you're talking about trying to trying to be competitive, trying to be efficient. When you know that you have to invest to just go about your core day to day business. Correct. Exactly. So that's a good point there, John, as you know, I should say, you know, if you look at, you know, the life science research buildings, there's a lot of different, you know, stringent codes and standards that apply to these type of facilities that don't necessarily apply to, you know, a non-lab type of facility, so. That's another, you know, you know, they have to maintain the compliance, you know, to, uh, you know, you know, if a regulatory body comes in and does an audit, you know, they have to have proof that, you know, they're operating these buildings in a safe manner, number one, but, you know, that's another challenge that I probably kind of overlooked there. Yeah, but it's, you know, it's kind of intrinsic into it, so it's not, not so much overlooking, but it's, it's for them, it's standard operating procedure no matter what they're doing, no matter what they're creating, it's kind of, it's a base platform of minimum requirement that has to be fulfilled, which is, which is not so easy to achieve perhaps in some cases. So, so I'd like to dive a little bit more into this time to market because that's an interesting one that's, you know, and, and, and all of us in the, in the world have kind of been living, we've been following a research development, you know, production and rollout phase or process in the life science market maybe like we've never done before when we've talked about vaccinations for COVID, you know, we, we've seen. So much effort going in from some of these companies you mentioned before, from March last year through to now when there are millions of doses running around the world. Uh, you know, what, what are some of, if we dive into that time to market, what are some of the real challenges about, about achieving that, and, and what are some of the phases that a company has to go through before we get that, that, uh, that product in our hands? Yeah, yeah. So yeah, if you look at, you know, what we've just, you know, have been through with COVID, you know, in particular is You know, really the time the market was really accelerated just because it had to be, right? They had to, you know, come up with a vaccine in a quick, you know, manner there to overcome this pandemic. But just in general, if you look at the life science market, you know, we tend to be both pandemic and recession proof. So, you know, life science is really kind of we can weather through the storm, you know, even if, you know, other markets tend to be down, you know, some of our markets were down over the last couple of years in particular with the pandemic. But you know, the time the market is critical for these guys because if you look at, you know, typical, you know, research and development, it can take, you know, 58, you know, 10 years to develop a particular vaccine or a medicine there, but with COVID they didn't have that luxury of that time, right? So they actually had to get out there and do the research and, you know, run it through the testing phases and get it to market quicker, quick as possible, so. You probably, you know, saw that, you know, Pfizer was one of them, Johnson and Johnson, Moderna, you know, were the first three kind of out of the gate there, so it was kind of a race, but, you know, more interesting is too is we saw a lot of these companies form partnerships that you typically don't, you know, see out there, you know, you know, we see competitors coming together and form partnerships to You know, get the vaccine out to market, you know, faster to overcome the challenges that we were faced with the COVID pandemic. I think we have a lot to offer if you look at, you know, Siemens in general, um, you know, hands down, you know, the capabilities that Siemens can provide our customers with, you know, as far as the digitalization, we can help them, uh, you know, automate their facilities and have them work more efficiently and effectively. Um, while, you know, keeping that facility in a safe, compliant manner as well. So, you know, the digitalization for, you know, the, the capabilities that we have with our digitalization capabilities, you know, is you're really hands down compared to our competitors out there, you know, you know, they, they, our competitors really can't compete with us on there. So we're really in a unique position, you know, to help our customers get to market faster and Um, and you know, build that strategy, you know, and we can actually look at, you know, further expanding our capabilities with, you know, standardization, you know, so we're not recreating a wheel for every type of project out there. So with our standardization with our engineering and startup procedures, you know, that really saves a lot of time and actually money too, so we can actually be a lot more cost effective compared to our competitors. Yeah, I understand. Uh, let's jump back to the time to market a little bit because you mentioned there 58, 10 years, you know, spending this amount of time on developing a product, can't be a cheap process. Uh, how do, you know, normally when you talk about this, this investment into research and development, we then talk about, OK, you've got a product, how, how long can you be unique? How long can you leverage that? How does it look in the life science market when they, when they develop these products, they invest so much time and effort and money into it. How does the time the market really affect their ability to, to then realize the opportunity? So that's critical for, you know, especially the large, large pharma when they spend the money to for the R&D on these new vaccines, new drugs, you know, new medicines out there. Really they have a short window to get it to market and take advantage of, you know, and kind of recoup their R&D costs before, you know, their patent runs out. You know, they actually have to file patents. And it's a very short window for, you know, that patent window that expires, and then that actually gives the opportunity for, you know, the generic companies, you know, the smaller companies to come in and develop a generic type of drug to be a cost effective option for that those that R&D that they've actually expended, you know, billions of dollars on, you know, a lot of times in this case is so. It's really critical, you know, for them to, you know, get their R&D done, run it through the testing phase, and, you know, get it to market and, you know, try to recoup as much cost as they can before, you know, the patent runs out and these generic companies come in and take advantage of the window that they have to develop a generic option. Yeah, right, so you put all this effort in, you have this really short window where you kind of have exclusivity in the market to a certain extent, correct. And once that expires, then you have a challenge because of course there are others that can do things differently or in a different place or whatever it might be. And this brings us back to one of the points you raised before around that digitalization and that flexibility. And the speed in adopting because you have to be able to to redeploy a facility that maybe was making product A yesterday, needs to make product B by in volume, you know, industrial volumes tomorrow, and the shortest period of time between A and B has a huge effect on the ability for that company to take advantage from that. How, how does that work? What, what are the challenges within that kind of process from changing from, you know, redeploying that or, uh, uh, you know, bringing something online, a manufacturing facility for a new product, and how can that digitalization aspect facilitate the speed and facilitate the accuracy while maintaining, maintaining all of the regulatory and, and safety requirements. So you know with our digitalization capabilities, you know, we can really, you know, assist our customers with, you know, keeping on track and making their operation and their production operation more efficient, you know, at that more so that allows them to. get their, their product out to the market quicker and take advantage of the, the, the added time factor that's, you know, that is realized there with taking advantage of technology for the efficiencies, but not, not, not to mention, you know, as far as the compliance tracking, you know, with the digitalization that we can do and help our customers with, you know, we can actually provide, you know, the electronic. Records that you know are required by these regulatory bodies to, you know, to prove that we're, you know, producing these products in a safe manner, number one, you know, that's key. Number one is you can't compromise safety to improve efficiency and the operation of the facility. I mean, safety is still number one. You hear about it in the market all the time where, you know, some of these large drug companies. They actually have, you know, an issue with their production, and they actually have to actually dispose of a lot of their product, which is a lot of money, you know, that's wasted at that point. So how, you know, with our digitalization, we can actually, you know, help our customers, um, be more effective and efficient and, you know, track, you know, the progress of the manufacturing process there as well. Yeah, and mitigate that risk because as you say you're turning something that could be a valuable product into just a liability and, and that, you know, the difference between throwing out everything you did in a day compared to everything you did between the 6 minutes or something like that can have a huge impact then on huge, yes, yep, huge. Perfect. Chad, thank you so much, uh, for this insight into the life science market. Uh, I, I'm excited to talk to you a little bit more about some of the really specific details here because as we talked about right at the start, you know, some of these, these, uh, these companies, some of these processes like you discussed, these are kind of daily, you know, they're household names for us somehow, uh, and it's interesting to understand the challenges that they overcome to, To create and deliver some of these, you know, these products, whether it be from big pharma or protecting us, you know, from a CDC or a WHO perspective or, or in those forensic applications, laboratories in hospitals and all these kinds of things, I think it's, it's really interesting. So thank you so much for the time and thanks for joining us. Thank you for the opportunity and I look forward to, you know, definitely further conversations with you folks. Bring it on, bring it on. And thank you to everyone who's listening to us as well. Remember to share, like, comment on this episode. Subscribe to us whether you're listening to us via one of your preferred podcast channels or watching this video on YouTube. Uh, check us out. There's new episodes every week after a little bit of a break over our Northern Hemisphere summer. But, uh, remember to keep your eye out for new, uh, technologies and, and new conversations with Chad in the near future. Thank you all.

Full transcript (WebVTT)